A Phase I and Pharmocologic Study of MM-121 in Patients With Refractory Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 15 Dec 2016
At a glance
- Drugs Seribantumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Biomarker; Therapeutic Use
- Sponsors Merrimack Pharmaceuticals
- 01 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Nov 2012 Planned end date changed from 1 Jul 2011 to 1 Mar 2013 as reported by ClinicalTrials.gov.
- 20 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.